The accumulation of
uremic toxins in
chronic kidney disease (CKD) induces
inflammation, oxidative stress and endothelial dysfunction, which is a key step in
atherosclerosis. Accumulating evidence indicates increased mitochondrial fission is a contributing mechanism for impaired endothelial function.
Hippurate, a uremic toxin, has been reported to be involved in
cardiovascular diseases. Here, we assessed the endothelial toxicity of
hippurate and the contribution of altered mitochondrial dynamics to
hippurate-induced endothelial dysfunction. Treatment of human aortic endothelial cells with
hippurate reduced the expression of
endothelial nitric oxide synthase (eNOS) and increased the expression of intercellular
cell adhesion molecule-1 (ICAM-1) and
von Willebrand factor (vWF). The mechanisms of
hippurate-induced endothelial dysfunction in vitro depended on the activation of
Dynamin-related
protein 1 (Drp1)-mediated mitochondrial fission and overproduction of mitochondrial
reactive oxygen species (mitoROS). In a rat model in which CKD was induced by 5/6
nephrectomy (CKD rat), we observed increased oxidative stress, impaired endothelium-dependent vasodilation, and elevated soluble
biomarkers of endothelial dysfunction (ICAM-1 and vWF). Similarly, endothelial dysfunction was identified in healthy rats treated with disease-relevant concentrations of
hippurate. In aortas of CKD rats and
hippurate-treated rats, we observed an increase in Drp1
protein levels and mitochondrial fission. Inhibition of Drp1 improved endothelial function in both rat models. These results indicate that
hippurate, by itself, can cause endothelial dysfunction. Increased mitochondrial fission plays an active role in
hippurate-induced endothelial dysfunction via an increase in mitoROS.